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and 0.657 (0.035) for their siblings. When analysis
of covariance allowing for the effect of gender and
BL (as a covariate) on HC was applied to the data,
no significant difference in HC at birth was found
between preschizophrenics and their siblings
(F0.43, d.f. 1,104, P0.52), nor was there an
interactingeffectof genderand thecaseâ€”sibling
status on HC (F=0.00, d.f.= 1,104, P@0.98). Next,
we performed paired t-tests by selecting 11 male
maleand6 female-femalesib-pairs.Themean (s.d.)
HC in preschizophrenics and in their siblings re
spectively were 33.9 (1.5) and 33.4 (1.2) cm (t 1.40,
d.f.l6,P0.18). The HCâ€”BLratios(s.d.)were
0.660 (0.030) for preschizophrenics and 0.653
(0.034) for their siblings (t0.78, d.f. 16, P0.17).
Again, no significant difference was detected. We
also examined gestational age (weeks) at delivery,
but no statistically significant difference was found
between the two groups (the mean age was 39.2 in
preschizophrenics and 39.7 weeks in siblings
(t=0.98,d.f.=15,P=0.34).
Thus, we failed to confirm the findings reported
by McNeil et al. This failure could be due to not all
the comparison group having passed through the
risk age of the disease. Also, the schizophrenic
patients and their siblings will share genes which
influence brain development â€”¿a comparison with
siblings may have biased our study.
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Lithium mutagenicity
Sat: Many fertile women receive prophylactic
lithium carbonate treatment (Schou, 1990). It is not
known whether the higher than expected frequency
of congenital anomalies reported among the off
spring of mothers receiving lithium therapy in the
last two decades (Warkany, 1988) is related to a
direct lithium toxicity, a mutagenic effect on germ
cells, or both. To our knowledge this is the first
case-controlled study blindly comparing patients
taking lithium with normal controls with regard to
the assessment of the frequency of chromosomal
lesions.
EightwhiteBrazilianpatients(mean (s.d.)age
37.50 (10.36) years) who had been receiving
continuous lithium therapy (mean dose 768.75
(139.05) mg/day) for at least one year were
selected from the Escola Paulista de Medicina's
Affective Disorders out-patient clinic and com
pared with 10 psychiatrically healthy drug-free
controls matched for sex and age who were
concomitantly drawn from the otolaryngologic
out-patient clinic of the same institution. A cyto
genetic analysis was carried out using standard
methods with blood lymphocytes cultured in a
folic-acid free medium. A total of 100 mitoses per
subjectwereanalysedwiththeinvestigatorblind
to group assignment. Chromosomal lesions were
observed by G-banding with trypsin stain for
localisation of the lesions. The results showed a
totalof 102and 96 lesionsscoredforcasesand
controls respectively. There was no difference
between groups (P>0. 10) concerning the number
of lesions, and there was no evidence of a special
distributionpatternof lesionsthroughoutthe
chromosomal map in either group.
These findings suggest that lithium has no
mutagenic activity at the level of resolution used
(400 bands). Recent reports have suggested that the
risk of thyroid and cardiovascular malformations,
H. KUNUGI especially the rare Ebstein's anomaly, remains con
N. TAKE! troversial (Zalzstein et al, 1990; Ferner & Smith,
1992;Jacobsonet al,1992).Accordingto our
results, a teratogenic effect of lithium would be
more easily explained by a direct toxic effect of
lithium carbonate rather than a mutagenic effect
on germ cells.
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High-dose antipsychotic medication
Sm: The problems of using high-dose antipsychotic
medication are highlighted by Thompson (for the
Royal College of Psychiatrists' Consensus Panel)
(BJP, April 1994, 164, 448-458, 1994) and Kane
(BJP, April 1994, 164, 431-432).
We have successfully reduced high-dose regimens
in a number of patients with severe, chronic schizo
phrenia, in both in- and out-patient settings.
Case 1 is a 50-year-old married woman, an
out-patient since her last admission 10 years ago,
and maintained on daily doses of 600 mg chlorpro
mazine, 600 mg lithium, 60 mg diazepam (20 mg
three times daily) and 20 mg procycidine, together
with 500 mg zuclopenthixol decanoate at 4-weekly
intervals. In October 1993 we introduced treatment
with risperidone, rising to a dose of 3 mg twice
daily.At thesametime,herothertreatmentswere
cautiously reduced, under the supervision of her
community psychiatric nurse. Chlorpromazine was
gradually withdrawn by reducing the dose by 50 mg
each day over a period of two weeks, depot zuclo
penthixol injections are similarly being reduced by
50 mg at each 4-weekly injection, diazepam was
reduced to 5 mg three times a day, and both lithium
and procyclidine were discontinued. Following the
introduction of risperidone and the gradual reduc
tion of her other medication, there has been a
significant change in the patient's mental state. Not
only has there been no return of active psychotic
symptoms but she has changed from taking no part
in family life to being able to manage home and
kitchen duties and being active in conversations.
Three other out-patients with similar clinical and
drug histories have gradually been switched to
risperidone. All have succeeded in gradual tran
sition without relapse and have experienced a
return of interest, activity and social involvement.
One example is case 2, a 34-year-old man main
tained for a number of years on daily doses of
800 mg chlorpromazine, 40 mg zuclopenthixol,
10 mg diazepam and 20 mg procyclidine. He had
a history of severe psychosis and violence, with
little recent progress. He is now managed on 4 mg
risperidone twice daily, having cooperated enthusi
astically in the withdrawal of his other medication.
His negative symptoms have ameliorated, he is
more at ease with himself and appears to enjoy a
better quality of life than before.
Patients may be weaned off high doses of neuro.
leptics and successfully maintained on risperidone.
In such patients, gradual dose reduction of conven
tional neuroleptics is important in maintaining
patients' confidence and to avoid rebound Parkin
sonism which has been observed after more sudden
withdrawal following very long-term treatment.
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Sinus bradycardia due to Nuvoxamine overdose
Sm: We report a case of fluvoxamine cardiotox
icity that manifested as marked bradycardia, and
required close medical monitoring.
Case report A 58-year-old woman with a bipolar affective
disorder had been hospitalised due to a major depressive
episode.Therapy with fluvoxaminewas commencedat a
daily dose of 250 mg. After a month of treatment, im
provement was noted. A night prior to her scheduled
discharge she attempted suicide by ingesting 5.5 g of
fluvoxamine. On examination several hours later the
patient was pale, severesinus bradycardia was found (32
beats per minute), and she complainedof severefatigue.
No medical intervention was necessary due to stable
haemodynamic parameters. The patient returned to
normal sinus rhythm within a couple of days.
Henry ci a! (1991) reported on sinus bradycardia in
15 of 310 cases with fluvoxamine overdose. Most
patients had mild adverse effects, none of which
required treatment. It is not clear what the direct
cause of bradycardia was.
Szabadi (Burton, 1991) referred to this issue by
mentioning that fluvoxamine blocks muscarinic re
sponses. Although its antimuscarinic potency is a
third of that of amitriptyline, it is usually prescribed
at higher doses. In addition, high single doses of
fluvoxamine seem to block 131and 132adrenorecep
tors, as is shown by the reduction of exercise
induced tachycardia. Therefore, the muscariic and
@3-blockingactivities of fluvoxamine may account
for the appearance of severe sinus bradycardia, and
for some unexplained deaths following fluvoxamine
overdose (Gamier et a!, 1993).
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